Review Article

Peroxisome Proliferator-Activated Receptors (PPARs) as Potential Inducers of Antineoplastic Effects in CNS Tumors

Lars Tatenhorst,1 Eric Hahnen, 2 and Michael T. Heneka 1

1 Department of Neurology, University of Bonn, Sigmund-Freud-Street 25, 53105 Bonn, Germany
2 Institute of Human Genetics, Institute of Genetics, and Center for Molecular Medicine Cologne (CMMC), University of Cologne, Kerpener street 34, 50931 Cologne, Germany

Correspondence should be addressed to Michael T. Heneka, heneka@uni-muenster.de

Received 1 March 2008; Revised 29 May 2008; Accepted 24 June 2008

Recommended by Dipak Panigrahy

The peroxisome proliferator-activated receptors (PPARs) are ligand-inducible transcription factors which belong to the superfamily of nuclear hormone receptors. In recent years it turned out that natural as well as synthetic PPAR agonists exhibit profound antineoplastic as well as redifferentiation effects in tumors of the central nervous system (CNS). The molecular understanding of the underlying mechanisms is still emerging, with partially controversial findings reported by a number of studies dealing with the influence of PPARs on treatment of tumor cells in vitro. Remarkably, studies examining the effects of these drugs in vivo are just beginning to emerge. However, the agonists of PPARs, in particular the thiazolidinediones, seem to be promising candidates for new approaches in human CNS tumor therapy.

Copyright © 2008 Lars Tatenhorst et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. REVIEW CRITERIA

For this review we searched NCBI PubMed articles including early-release publications. Search terms included peroxisome proliferator-activated receptor (PPAR) in conjunction with “glioma” or “glioblastoma” or “astrocytoma” or “neuroblastoma.” The abstracts of retrieved citations were reviewed and prioritized by relevant content. Full articles were obtained and references were checked for additional material when appropriate. Only papers published in English between 1995 and 2008 were included.

2. PPARs

The peroxisome proliferators-activated receptors (PPARs) are ligand-inducible transcription factors which belong to the superfamily of phylogenetically related proteins termed nuclear hormone receptors (NHRs). Three different PPAR isotypes (PPARα, PPARβ/δ, also called δ, and PPARγ) have been identified in various species and show structural homology [1, 2]. PPARγ is found in two different isoforms, PPARγ1 and PPARγ2 [3].

PPARα, PPARβ/δ and PPARγ show unique spatiotemporal tissue-dependent patterns of expression during fetal development in a broad range of cell types with ectodermal, mesodermal, or endodermal origin. PPARs are involved in several aspects of tissue differentiation and development, such as the differentiation of the adipose tissue, brain, placenta, and skin [4]. Therefore, it appears that the PPAR isoforms developed from a common PPAR gene with broad ligand-binding specificity, itself derived from the ancestral orphan receptor [5].

PPARs regulate gene expression via multiple mechanisms, thereby functioning as obligate heterodimers with retinoid-X-receptors (RXRs). Like the other members of the NHR superfamily, PPARs are composed of four domains. The highly conserved DNA-binding domain together with its zinc finger domain is a common attribute of all family members. The DNA binding domain is linked to the C-terminal ligand binding domain by the hinge region. The E/F domain is responsible for the dimerization of PPARs with RXRs and the ligand-dependent transactivation function of the receptor. The N-terminal domain finally is involved in the ligand-independent regulation of the receptor activity (reviewed in [6]).
PPARs stimulate gene expression through binding to conserved DNA sequences, termed peroxisome-proliferator response elements (PPREs), present in the promoter region of their target genes. In the absence of ligands, these heterodimers are physically associated with coressor complexes which suppress gene transcription [4]. However, upon binding of a ligand to the receptor, the NCor-containing coressor complexes are dismissed and replaced with coactivator complexes. These coactivators are then linked to the basal transcriptional apparatus, thereby activating gene transcription [7].

PPARs act principally as lipid sensors and regulate whole body metabolism in response to dietary lipid intake and direct their subsequent metabolism and storage [8]. The prototypic member of the family, PPARα, was initially reported to be induced by peroxisome proliferators, and now denotes the subfamily of three related receptors. The natural ligands of these receptors are dietary lipids and their metabolites. The specific ligands interacting with the individual receptors have been difficult to establish, owing to the relatively low-affinity interactions and broad ligand specificity of the receptors.

PPARα acts primarily to regulate energy homeostasis through its ability to stimulate the breakdown of fatty acids and cholesterol, driving gluconeogenesis and reduction in serum triglyceride levels. This receptor acts as a lipid sensor, binding fatty acids and initiating their subsequent metabolism. PPARα binds a number of lipids including fatty acids, eicosanoids, and other natural lipid ligands. Its dominant action is to stimulate adipocyte differentiation and to direct lipid metabolites to be deposited in this tissue. PPARγ operates at the critical metabolic intersection of lipid and carbohydrate metabolism. PPARγ activation is linked to reduction in serum glucose levels, likely as a secondary effect of its ability to regulate endocrine factors. It is this latter activity that has led to the development of specific PPARγ agonists for the treatment of type-2 diabetes [9]. The PPARβ/δ binds and responds to VLDL-derived fatty acids, eicosanoids including prostaglandin A1 [10] and appears to be primarily involved in fatty acid oxidation, particularly in muscle.

Binding of PPARs to their specific ligands leads to conformational changes which allow co-repressor release and co-activator recruitment. Even though all PPARs can be attributed to a common ancestral nuclear receptor, each PPAR isotype has its own properties with regard to ligand binding. Synthetic thiazolidinediones (TZDs), which are commonly prescribed for the treatment of type-2 diabetes, are selective PPARγ ligands. Naturally occurring PPARγ ligands include eicosanoids and the cyclopentenone prostaglandin 15d-PGJ2. The best characterized PPARγ agonists are the TZDs including pioglitazone (Actos) and rosiglitazone (Avandia), which are Food and Drug Association (FDA) approved for treatment of type-2 diabetes. The TZD troglitazone (Rezulin) was introduced in the late 1990s but turned out to be associated with an idiosyncratic reaction leading to drug-induced hepatitis. It was withdrawn from the US market in 2000, and from other markets soon afterwards. There are a number of non-TZD-based PPARγ agonists, such as GW78456 and others that have been developed. PPARα ligands include fibrates that are commonly used for the treatment of hypertriglyceridemia and the synthetic agonists WY14,643 and GW7647. PPARβ/δ agonists include the prostacyclin PG12, and synthetic agents including GW0742, GW501516, and GW7842. All three PPAR isotypes can be activated by polyunsaturated fatty acids with different affinities and efficiencies [8, 11]. An overview addressing the affinity of several natural and synthetic ligands has been summarized recently [12].

All PPARs have been described in the adult and developing brain as well as in the spinal cord. Furthermore, it has been suggested that PPAR activation in neurons may directly influence neuron cell viability and differentiation [13–17]. While PPARβ/δ has been found in neurons of numerous brain areas, PPARα and γ have been localized to more restricted brain areas [18, 19]. The localization of PPARs has also been investigated in purified cultures of neural cells. PPARβ/δ is expressed in immature oligodendrocytes where its activation promotes differentiation, myelin maturation and turnover [20, 21]. The γ isotype is the dominant isoform in microglia. Astrocytes possess all three PPAR isotypes, although to different degrees depending on the brain area and animal age [22, 23].

The role of PPARs in the CNS is mainly related to lipid metabolism; however, these receptors have been implicated in neural cell differentiation and death as well as in inflammation and neurodegeneration. The expression of PPARγ in the brain has been extensively studied in relation to inflammation and neurodegeneration [14]. PPARγ has been suggested to be involved in the acetylcholine metabolism [24] and to be related to excitatory amino acid neurotransmission and oxidative stress defense [18]. However, mice lacking PPARα function appear healthy and fertile and do not show neurological phenotypes, suggesting that PPARα is dispensable for brain development [25]. In contrast, loss of PPARγ has been shown to be embryonically lethal [26]. Whereas PPARβ/δ remains highly expressed in the rat CNS, the expression of PPARα and γ decreases postnatally in the brain [27]. In retina, all three receptors are expressed [23, 27, 28]. Even though this pattern of expression, which is isotype-specific and regulated during development, suggests that the PPARs may play a role during the formation of the CNS, their function in this tissue is still poorly understood. Both in vitro and in vivo observations show that PPARβ/δ is the prevalent isoform in the brain being found in all cell types, whereas PPARα is expressed at very low levels predominantly in astrocytes [29]. Acyl-CoA synthetase 2, which is crucial in fatty acid utilization, is regulated by PPARβ/δ at the transcriptional level, providing a facile measure of PPARβ/δ action. This observation strongly suggests that PPARβ/δ participates in the regulation of lipid metabolism in the brain. This hypothesis is further supported by the observation that PPARβ/δ null mice exhibit an altered myelination of the corpus callosum. Such a defect was not observed in other regions of the central nervous system, and the expression of mRNA encoding proteins involved in the myelination process remained unchanged in the brain [30].
As mentioned above, PPARs were at first identified as controllers of lipid metabolism. Presently, it turned out that PPARs also play a role in controlling important cellular functions like energy homeostasis, diabetes, cell proliferation and cell death, differentiation, inflammation, and even cancer [6, 31]. Especially PPARγ and its agonists have been demonstrated to induce antineoplastic effects in several types of cancer (reviewed in [7]). In the following we focus on the role of PPARs as potential inducers of antineoplastic effects in highly abundant CNS tumors, namely astroglioma and neuroblastoma.

3. ASTROGLIOMA

Malignant astrocytic gliomas represent the largest proportion of all primary brain tumors in adults [32, 33]. The characteristic feature of glioma cells is a high proliferation rate, accompanied by the ability to invade far into the healthy brain tissue. According to the WHO classification of tumors of the nervous system [32], gliomas are ranked as the most frequent brain tumor, which is also the most frequent brain tumor, is accompanied by the ability to invade far into the healthy brain tissue. According to the WHO classification of tumors of the nervous system [32], gliomas are ranked as the most frequent brain tumor, which is also the most frequent brain tumor, is accompanied by the ability to invade far into the healthy brain tissue. According to the WHO classification of tumors of the nervous system [32], gliomas are ranked as the most frequent brain tumor, which is also the most frequent brain tumor, is accompanied by the ability to invade far into the healthy brain tissue. According to the WHO classification of tumors of the nervous system [32], gliomas are ranked as the most frequent brain tumor, which is also the most frequent brain tumor, is accompanied by the ability to invade far into the healthy brain tissue. According to the WHO classification of tumors of the nervous system [32], gliomas are ranked as the most frequent brain tumor, which is also the most frequent brain tumor, is accompanied by the ability to invade far into the healthy brain tissue. According to the WHO classification of tumors of the nervous system [32], gliomas are ranked as the most frequent brain tumor, which is also the most frequent brain tumor, is accompanied by the ability to invade far into the healthy brain tissue.

All isoforms of PPARs are expressed in the brain [35, 36] as well as in a variety of rat and human astroglial cell lines [7, 37–44]. PPARγ has been shown to be expressed at high levels in human glioblastomas [31, 37, 45, 46]. Based on findings in other neoplastic disease, several natural and synthetic ligands of PPARs have been tested for their efficacy in the treatment of astroglial glioma. Bezafibrate and gemfibrozil, both PPARα agonists, inhibited the cellular viability of glioblastoma cell lines [47]. A different effect was observed when human T98G glioblastoma cells were treated with other PPARα ligands, clofibrate and Wy-14,643. These ligands strongly downregulated the expression of semaphorin 6B, a member of the semaphorin family of axon guidance molecules [39], suggesting suppression of glioma invasion mechanisms by these PPARα agonists. However, no direct influence of Wy-14,643 on proliferation or induced cell death was observed in either human or rat glioma cells [43].

Treatment with conjugated linoleic acid (CLA) inhibited growth in primary human glioblastoma cells as well as ADF glioblastoma cells [13, 40, 48]. In ADF cells this was associated with an increase of PPARα and a decrease of PPARβ/δ expression, whereas PPARγ levels were unaltered [40]. Cimini et al. found that CLA and the PPARγ-specific agonist GW347845 reduced glioma cell growth and induced apoptosis [13, 48]. The authors suggested that this effect was mediated by PPARγ activation. This conclusion was supported by the finding that the PPARγ antagonist GW259662 completely prevented both the CLA and GW347854X-induced effects on cell growth and apoptosis. Furthermore, PPARγ agonists reduced cell adhesion, cell migration, and tumor invasion which was associated with a decrease in matrix metalloproteinase 2 (MMP2) levels. The authors stated that activation of PPARγ is likely to be responsible for these latter effects, since the PPARγ agonist GW259662 completely abolished these effects [13]. Furthermore, treatment with CLA and GW347845 significantly decreased VEGF isoforms, indicating that PPARγ may also inhibit angiogenesis in gliomas [48].

Perez-Ortiz et al. reported that generation of reactive oxygen species (ROSs) was likely to be responsible for glitazone-induced glial cell death [35, 49], which is in line with findings of Kang et al. [50]. Interestingly, in four different glioma cell lines (A172, U87-MG, M059K, M059J) rosiglitazone led to inhibition of proliferation and induction of apoptosis in a PPARγ-dependent way since there the antagonist GW9662 partially reverted this effect [46]. Ciglitazone and the putative natural PPARγ ligand PGJ2 inhibited proliferation and induced apoptotic cell death in human [38] and rat glioma cells, and apoptotic cell death was correlated with the upregulation of Bax and Bad protein levels [43]. Similar effects have been described by Zang et al. [44], who also reported that a combination of pioglitazone with all-trans retinoic acid (ATRA) increased the cytotoxic effect. Tetradecylthioacetic acid (TTA), a saturated fatty acid and PPAR ligand, inhibited growth of BT4Cn rat glioma cells at increased levels as compared to the PPARγ ligand rosiglitazone [37]. Furthermore, TTA reduced tumor growth and led to a longer survival of rats with implanted BT4Cn tumors. The use of the PPARγ antagonist GW9662 reversed the effect of rosiglitazone but not for TTA, indicating that TTA might act both via PPARγ-dependent and PPARγ-independent pathways [37].

Grommes et al. reported that the nonthiazolidinedione tyrosine-based PPARγ ligand GW7845 reduced viability of rat C6 and human glioma cells and induced apoptotic cell death in a PPARγ-dependent mechanism as shown by the inhibition of these effects by the specific antagonist GW9662 [51]. Primary astrocytes were not affected, demonstrating the specificity of the effects of GW7845 on neoplastic cell types. GW7845 also reduced proliferation of rat C6 glioma cells and reduced both the migration and invasion of glioma cells [51]. These investigators have subsequently reported [52] that the PPARγ agonist pioglitazone reduced cellular viability of rat and human glioma cell in vitro. Furthermore proliferation in rat glioma cells was inhibited, as measured by Ki-67 expression. Glioma cells overexpressing PPARγ cDNA showed reduced cellular viability after pioglitazone treatment, whereas treatment of glioma cells overexpressing a mutant cDNA lacking transcriptional activity, showed no antineoplastic effects [52]. Grommes et al. extended these findings to in vivo studies, using a C6 rat glioma model [52]. In this study, tumor volumes were dramatically reduced following pioglitazone administration intracerebrally, as well as orally, indicating that pioglitazone is able to cross the blood-brain barrier (BBB). It has not been established whether TZDs other than pioglitazone penetrate...
the BBB. However, in vitro studies provide evidence that troglitazone is actively incorporated by the bidirectional transporter Oatp14 (Slco1c1) expressed in brain capillary endothelial cells, which is likely to provide homeostasis of troglitazone and may be of other TZDs [53]. Treated animals showed drug-induced apoptosis in the tumors by activation of proapoptotic proteins. Grommes and coworkers also observed decreased tumor invasion in vivo which was correlated with reduced MMP9 levels. Indeed, PPARγ agonists suppressed tumor migration in vitro in a Boyden chamber assay. Finally, they described a pioglitazone-induced upregulation of the astrocytic redifferentiation marker CS-56 in tumor cells both in vivo and in vitro. Primary astrocytes were not affected by pioglitazone, indicating the restriction of these effects to neoplastic cell types [52]. A possible explanation for this neoplastic specificity is given by Spagnolo et al., who showed differences in metabolic responses in GL261 glioma cells as compared to primary astrocytes when treated with the TZD troglitazone [54].

The same authors also presented a study exploring C57/B6 mice with an intracerebral glioma derived from GL261 cells [55]. Mice were treated with a combined therapy of interleukin (IL)-2-secreting syngeneic/allogeneic fibroblasts administered into the tumor bed along with the TZD pioglitazone. In contrast to the data of Grommes et al., only intracerebrally administered pioglitazone prolonged the survival of mice harboring an intracerebral glioma, whereas pioglitazone administered orally showed no effect. Finally, combination of pioglitazone and IL-2-secreting fibroblasts significantly prolonged the survival of the treated mice as compared to untreated animals [55].

Using an organotypic glioma invasion model, closely resembling extracellular matrix environment present in the brain, Coras et al. show that micromolar doses of troglitazone blocked glioma progression without neurotoxic damage to the organotypic neuronal environment observed [56]. The authors stated that the intriguing antiglioma property of troglitazone appears to be only partially based on its moderate cytostatic effects. Concordant with the data presented by Grommes et al., the authors showed that troglitazone effectively inhibits glioma cell migration and brain invasion. Interestingly, the antimigratory effects of troglitazone could be mimicked by inhibition of TGF-β signaling which has shown to be intimately involved in glioma cell migration, suggesting both mechanisms to be interlinked. In this study, the authors identified troglitazone...
as a potent inhibitor of TGF-β release, suggesting that troglitazone reduced glioma cell motility by counteracting TGF-β signaling [56].

More than 10 years ago, Prasanna et al. [57] reported that treatment with lovastatin (a HMG-CoA reductase inhibitor) led to growth arrest in glioma cells, accompanied with an increased expression of PPAR. A combination therapy of lovastatin and the PPARγ agonist troglitazone reduced cellular viability in the D83TRG-05MG human glioblastoma cell line [58]. Interestingly, the combination of lovastatin with two other PPARγ agonists, rosiglitazone and ciglitazone, did not lead to the same effect. The authors suggested that it may be possible that PPARγ is an essential, but not sufficient, factor in this synergism.

PPAR agonists have also been shown to exhibit effects on tumor biology through PPAR-independent mechanisms. For example, the PPARα/γ dual agonist TZD 18 inhibited growth of T98G human glioblastoma cells and induced apoptosis through PPAR-independent mechanisms, since their respective antagonists MK-886 and GW9662 did not reverse this effect [59]. The TZD-mediated antineoplastic properties from PPARγ were argued to arise from off-target, receptor-independent actions of the drugs as well as those of rosiglitazone and pioglitazone [35, 38, 43, 60]. The glitazones were toxic for the human glioma cell line U251 and rat glioma cell line C6, but not for primary rat astrocytes [43]. Indeed, PPARγ seems not to be involved in these effects of the TZDs, since the inhibitor GW9662 had nearly no effect on attenuation of cytotoxicity. Using PPARγ positive and PPARγ deficient mouse embryonic stem (ES) cells, it has been demonstrated that the TZD troglitazone inhibited the growth of tumors formed by injection of PPARγ+ and PPARγ− cells to the same extent, indicating that PPARγ is not essential for the antiproliferative effects of troglitazone [60]. Moreover, troglitazone derivatives which are unable to activate PPARγ suppress cancer cell proliferation similar to troglitazone, giving further evidence that the antiproliferative effects of troglitazone are at least in part PPARγ-independent [61]. Furthermore, troglitazone sensitized human glioma cells to TRAIL-induced apoptosis in a process independent of PPARγ [62, 63]. Troglitazone treatment led to a marked downregulation of the antiapoptotic proteins FLIP and survivin [63] as well as Bcl-2 [62] and so could possibly counteract the capability of tumor cells to become resistant to apoptosis. Hence a combination therapy of troglitazone and TRAIL might be a promising experimental approach. Conversely, in A172 human glioma cells Kang and colleagues showed that the TZD ciglitazone induced cell death dependent of PPARγ, but independent of caspase and AIF. Furthermore, the authors demonstrated that downregulation of XIAP and survivin is involved in the cell death mechanism [50]. A possible explanation for the differentiative effects of PPARγ agonists was supposed to rely on PPARγ dysfunction. Single strand conformational polymorphism (SSCP) analysis was carried out in different tumor and nontumor tissues, showing somatic loss-of-function mutations in different carcinomas [64, 65]. Genetic analysis of American patients with glioblastoma multiforme revealed an overrepresentation of the H449H polymorphism in the PPARγ gene, possibly being an important low penetrance susceptibility locus for glioneural tumors [66].

4. NEUROBLASTOMA

Neuroblastoma is a phenotypically heterogeneous tumor, containing cells of neuronal, melanocytic or glial/Schwann cell lineage. Regardless of the phenotype, PPARγ is expressed in neuroblastoma cell lines [67], in primary neuroblastoma cells [7] as well as in samples of patients harbouring neuroblastoma [68]. Data about the expression of PPARβ/δ in neuroblastomas are scarce [69–71], and only a few studies report the expression of PPARα at mRNA or protein level in human neuroblastoma cell lines [71–74]. Therefore, most studies that assess the influence of PPARs on treatment of neuroblastoma evaluate the impact of its natural or synthetic ligands.

The putative natural PPARγ agonist 15d-PGJ2 inhibits cellular growth, decreases cellular viability and induces apoptosis in human neuroblastoma cells in vitro [67, 69, 74–76]. Rodway et al. [74] show that the PPARα agonist WY-14643 has no effect on the growth of the IMR32 neuroblastoma cell line, whereas PGJ2 induces growth inhibition in the same neuroblastoma cells. This occurs through programmed cell death type II or autophagy, and the serum lysolipid LPA is responsible for modulating this cellular response. In the neuroblastoma cell line ND-7, the same group shows that the degree of PPARα activation induced by PGJ2 is modulated through an interaction with retinoloblastoma protein (Rb) and the class I histone deacetylase 3 (HDAC3) [75]. A combination therapy consisting of PGJ2 and the histone deacetylase inhibitor trichostatin A (TSA) enhanced the growth inhibition effects and is therefore proposed as a promising new strategy in the treatment of neuroblastoma. It should be noted that the effects of 15d-PGJ2 can also arise from its actions on the NFκB pathway [77]. Di Loreto et al. report that a specific PPARβ agonist as well as oleic acid induced redifferentiation in SH-SY5Y neuroblastoma cells [70].

The best studied synthetic PPARγ agonists are the TZD class of antidiabetic drugs, also referred to as glitazones [7]. Valentiner et al. [78] tested four glitazones (ciglitazone, pioglitazone, troglitazone, rosiglitazone) and reported their in vitro effects on cell growth in seven human neuroblastoma cell lines (Kelly, LAN-1, LAN-5, LS, IMR-32, SK-N-SH, SH-SY5Y). All the glitazones inhibited cell growth and viability of the human neuroblastoma cell lines in a dose-dependent manner, whereas the effectiveness of the single drugs differed strongly between cell lines. Similar results for ciglitazone and rosiglitazone have been reported [75, 79]. Cellai et al. show that high concentrations of rosiglitazone significantly inhibit cell adhesion in vitro, invasiveness and apoptosis in SK-N-AS, but not in SH-SY5Y human neuroblastoma cells [79]. The authors argued that this effect may be related to cellular differences in PPARγ transactivation. Furthermore, Jung et al. report that the TZD rosiglitazone protects SH-SY5Y cells against MPP+ as well as acetaldehyde-induced cytotoxicity, which may be ascribed to the induction of the...
expression of antioxidant enzymes and also to the regulation of Bcl-2 and Bax expression by rosiglitazone [80, 81].

5. CONCLUSION

The understanding of the molecular mechanisms underlying the antineoplastic effects mediated by PPAR agonists is still emerging. Over the past years, an increasing number of reports were published, presenting evidence for several involved pathways concerning cell cycle arrest, apoptosis, redifferentiation and inhibition of invasion/migration, that have been found to be affected by PPAR agonist treatment. Figure 1 presents an overview of signal mechanisms involved in the antineoplastic effects of PPAR ligands. Interestingly, there are partially controversial findings regarding the receptor dependency of the observed effects. Besides the number of natural and synthetic ligands, as well as to the number of different tumor cell lines used, a further explanation may be that most studies were performed on long-term cultured cell lines which may have undergone alterations while being in cell culture. Only few studies use primary cell cultures of tumor cells or organotypic models, like Benedetti et al. or Coras et al. [48, 56], trying to resemble natural conditions as close as possible. Remarkably, studies examining the effects of PPAR agonists in vivo are just emerging for gliomas [52, 55], and are still missing for neuroblastomas.

From all natural and synthetic PPAR ligands, the group of thiazolidinediones is the one with the best characterized antineoplastic properties. The fact that TZDs like pioglitazone (Actos) and rosiglitazone (Avandia) are FDA-approved for treatment of type-2 diabetes and therefore readily available for clinical studies may be the main reason for this. Very recently, a phase 2 clinical study was published, presenting for the first time a combination of low-dose chemotherapy with COX-2 inhibitors and PPARγ agonists in high-grade gliomas [82]. Unfortunately, the trial had to be closed prematurely, due to the moderate efficacy as compared to other clinical trials, which however investigated PPARγ agonist treatment of different tumor entities. It is questionable whether the tumor biology of astrogloma, which are extremely heterogeneous and rarely metastasize, can be compared to these different tumors, and thus the degree of response to a PPARγ agonist-based therapy. Of note, depending on the particular astrogloma and region within the tumor, the poor blood brain barrier penetration of the TZDs may also account for limited efficacy. Therefore, further in vivo studies are warranted to unravel the molecular mechanisms underlying the antineoplastic effects of PPAR agonists in malignant astrocytic gliomas.

Nevertheless, agonists of PPARs, in particular the TZDs, seem to be promising candidates for new therapeutic approaches in human CNS tumor therapy due to their profound antiproliferative and anti-inflammatory effects as well as their positive effects on apoptosis and redifferentiation.

REFERENCES

[1] T. Lemberger, B. Desvergne, and W. Wahli, “Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology,” Annual Reviews of Cell & Developmental Biology, vol. 12, pp. 355–363, 1996.
[2] M. Robinson-Rechavi, A.-S. Carpentier, M. Duffraisse, and V. Laudet, “How many nuclear hormone receptors are there in the human genome?” Trends in Genetics, vol. 17, no. 10, pp. 554–556, 2001.
[3] L. Fajas, D. Auboeuf, E. Raspé, et al., “The organization, promoter analysis, and expression of the human PPARγ gene,” The Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997.
[4] B. Desvergne and W. Wahli, “Peroxisome proliferator-activated receptors: nuclear control of metabolism,” Endocrine Reviews, vol. 20, no. 5, pp. 649–688, 1999.
[5] H. Escriva, E. Delaunay, and V. Laudet, “Ligand binding and nuclear receptor evolution,” BioEssays, vol. 22, no. 8, pp. 717–727, 2000.
[6] S. Kersten and W. Wahli, “Peroxisome proliferator activated receptor agonists,” EXS, vol. 89, pp. 141–151, 2000.
[7] C. Grommes, G. E. Landreth, and M. T. Heneka, “Antineoplastic effects of peroxisome proliferator-activated receptor γ agonists,” The Lancet Oncology, vol. 5, no. 7, pp. 419–429, 2004.
[8] L. Michalik, I. Auwerx, J. P. Berger, et al., “International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006.
[9] T. M. Willson, M. H. Lambert, and S. A. Kliewer, “Peroxisome proliferator-activated receptor γ and metabolic disease,” Annual Review of Biochemistry, vol. 70, pp. 341–367, 2001.
[10] G. D. Barish, “Peroxisome proliferator-activated receptors and liver X receptors in atherosclerosis and immunity,” The Journal of Nutrition, vol. 136, no. 3, pp. 690–694, 2006.
[11] G. Krey, O. Braissant, F. L’Horset, et al., “Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay,” Molecular Endocrinology, vol. 11, no. 6, pp. 779–791, 1997.
[12] A. Bernardo and L. Minghetti, “PPAR-γ agonists as regulators of microglial activation and brain inflammation,” Current Pharmaceutical Design, vol. 12, no. 1, pp. 93–109, 2006.
[13] A. Cimini, L. Cristiano, S. Colafarina, et al., “PPARγ-dependent effects of conjugated linoleic acid on the human glioblastoma cell line (ADF),” International Journal of Cancer, vol. 117, no. 6, pp. 923–933, 2005.
[14] M. T. Heneka, T. Klockgether, and D. L. Feinstein, “Peroxisome proliferator-activated receptor-γ ligands reduce neuronal inducible nitric oxide synthase expression and cell death in vivo,” The Journal of Neuroscience, vol. 20, no. 18, pp. 6862–6867, 2000.
[15] N. C. Inestrosa, J. A. Godoy, R. A. Quintanilla, C. S. Koenig, and M. Bronfman, “Peroxisome proliferator-activated receptor-γ is expressed in hippocampal neurons and its activation prevents β-amyloid neurodegeneration: role of Wnt signaling,” Experimental Cell Research, vol. 304, no. 1, pp. 91–104, 2005.
[16] K. S. Park, R. D. Lee, S.-K. Kang, et al., “Neuronal differentiation of embryonic midbrain cells by upregulation of peroxisome proliferator-activated receptor-gamma via the JNK-dependent pathway,” Experimental Cell Research, vol. 297, no. 2, pp. 424–433, 2004.
[17] S. A. Smith, G. R. Monteith, J. A. Robinson, N. G. Venkata, F. J. May, and S. J. Robert-Thomson, “Effect of the peroxisome
proliferator-activated receptor β activator GW0742 in rat cultured cerebellar granule neurons,” *Journal of Neuroscience Research*, vol. 77, no. 2, pp. 240–249, 2004.

[18] S. Moreno, S. Farioli-Vecchioli, and M. P. Cerù, "Immunolocalization of peroxisome proliferator-activated receptors and retinoid X receptors in the adult rat CNS," *Neuroscience*, vol. 123, no. 1, pp. 131–145, 2004.

[19] J. W. Woods, M. Tanen, D. J. Figueroa, et al., “Localization of PPARβ in murine central nervous system: expression in oligodendrocytes and neurons,” *Brain Research*, vol. 975, no. 1–2, pp. 10–21, 2003.

[20] A. Ciminì, L. Cristiano, A. Bernardo, S. Farioli-Vecchioli, S. Stefanini, and M. P. Cerù, “Presence and inducibility of peroxisomes in a human glioblastoma cell line,” *Biochimica et Biophysica Acta*, vol. 1474, no. 3, pp. 397–409, 2000.

[21] I. Saluja, J. G. Granneman, and R. P. Sko, “PPAR δ agonists stimulate oligodendrocyte differentiation in tissue culture,” *Glia*, vol. 33, no. 3, pp. 191–204, 2001.

[22] L. Cristiano, A. Bernardo, and M. P. Cerù, “Peroxisome proliferator-activated receptors (PPARs) and peroxisomes in rat cortical and cerebellar astrocytes,” *Journal of Neurocytology*, vol. 30, no. 8, pp. 671–683, 2001.

[23] T. E. Cullingford, K. Bhakoo, S. Peuchen, C. T. Dolphin, R. Patel, and J. B. Clark, “Distribution of mRNAs encoding the peroxisome proliferator-activated receptor α, β, and γ and the retinoid X receptor α, β, and γ in rat central nervous system,” *Journal of Neurochemistry*, vol. 70, no. 4, pp. 1366–1375, 1998.

[24] S. Farioli-Vecchioli, S. Moreno, and M. P. Cerù, “Immunocytochemical localization of acyl-CoA oxidase in the rat central nervous system,” *Journal of Neurocytology*, vol. 30, no. 1, pp. 21–33, 2001.

[25] S. S. T. Lee, T. Pineau, J. Drago, et al., “Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators,” *Molecular and Cellular Biology*, vol. 15, no. 6, pp. 3012–3022, 1995.

[26] Y. Barak, M. C. Nelson, E. S. Ong, et al., “PPARγ is required for placental, cardiac, and adipose tissue development,” *Molecular Cell*, vol. 4, no. 4, pp. 385–395, 1999.

[27] O. Braissant, F. Foufelle, C. Scotto, M. Dauça, and W. Wahli, “Differential expression of peroxisome proliferator-activated receptors (PPARs): tissue distribution of PPAR-α, -β, and -γ in the adult rat,” *Endocrinology*, vol. 137, no. 1, pp. 354–366, 1996.

[28] O. Braissant and W. Wahli, "Differential expression of peroxisome proliferator-activated receptor-α, -β, and -γ during rat embryonic development," *Endocrinology*, vol. 139, no. 6, pp. 2748–2754, 1998.

[29] S. Basu-Modak, O. Braissant, P. Escher, B. Desvergne, P. Honegger, and W. Wahli, “Peroxisome proliferator-activated receptor β regulates acyl-CoA synthetase 2 in reaggregated rat brain cell cultures,” *The Journal of Biological Chemistry*, vol. 274, no. 50, pp. 35881–35888, 1999.

[30] J. M. Peters, S. S. T. Lee, W. Li, et al., “Growth, adipose, brain, and skin alterations resulting from targeted disruption of the mouse peroxisome proliferator-activated receptor β(0),” *Molecular and Cellular Biology*, vol. 20, no. 14, pp. 5119–5128, 2000.

[31] J. Ehrmann Jr., N. Vavrusová, Y. Collan, and Z. Kolář, “Peroxisome proliferator-activated receptors (PPARs) in health and disease,” *Biomedical Papers*, vol. 146, no. 2, pp. 11–14, 2002.

[32] P. Kleihues, D. N. Louis, B. W. Scheithauer, et al., “The WHO classification of tumors of the nervous system,” *Journal of Neuropathology & Experimental Neurology*, vol. 61, no. 3, pp. 215–225, 2002.

[33] A. Behin, K. Hoang-Xuan, A. F. Carpentier, and J.-Y. Delattre, “Primary brain tumours in adults,” *The Lancet*, vol. 361, no. 9534, pp. 323–331, 2003.

[34] A. Giese, R. Bjerkvig, M. E. Berens, and M. Westphal, “Cost of migration; invasion of malignant gliomas and implications for treatment,” *Journal of Clinical Oncology*, vol. 21, no. 8, pp. 1624–1636, 2003.

[35] J. M. Pérez-Ortiz, P. Tranque, C. P. Vaquero, et al., “Glitazones differentially regulate primary astrocyte and glioma cell survival. Involvement of reactive oxygen species and peroxisome proliferator-activated receptor γ,” *The Journal of Biological Chemistry*, vol. 279, no. 10, pp. 8976–8985, 2004.

[36] M. Ricote, A. C. Li, T. M. Willson, C. J. Kelly, and C. K. Glass, “The peroxisome proliferator-activated receptor γ is a negative regulator of macrophage activation,” *Nature*, vol. 391, no. 6662, pp. 79–82, 1998.

[37] K. Berge, K. J. Tronstad, E. N. Flindt, et al., “Tetradecylthioacetic acid inhibits growth of rat glioma cells ex vivo and in vivo via PPAR-dependent and PPAR-independent pathways,” *Carcinogenesis*, vol. 22, no. 11, pp. 1747–1755, 2001.

[38] N. Chattopadhyay, D. P. Singh, O. Heese, et al., “Expression of peroxisome proliferator-activated receptors (PPARs) in human astrocytic cells: PPARγ agonists as inducers of apoptosis,” *Journal of Neuroscience Research*, vol. 61, no. 1, pp. 67–74, 2000.

[39] P. Collet, L. Domenjoud, M. D. Devignes, H. Murad, H. Schohn, and M. Dauça, “The human semaphorin 6B gene is down regulated by PPARs,” *Genomics*, vol. 83, no. 6, pp. 1141–1150, 2004.

[40] M. Magniòra, M. Bologna, M. P. Cerù, et al., “An overview of the effect of linoleic and conjugated-linoleic acids on the growth of several human tumor cell lines,” *International Journal of Cancer*, vol. 112, no. 6, pp. 909–919, 2004.

[41] M. G. Posch, C. Zang, W. Mueller, U. Lass, A. von Deimling, and E. Elstner, “Somatic mutations in peroxisome proliferator-activated receptor-γ are rare events in human cancer cells,” *Medical Science Monitor*, vol. 10, no. 8, pp. BR250–BR254, 2004.

[42] N. Strakova, J. Ehrmann, C. Dzubak, J. Bouchal, and Z. Kolar, “The synthetic ligand of peroxisome proliferator-activated receptor-γ cigitazone affects human glioblastoma cell lines,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 309, no. 3, pp. 1239–1247, 2004.

[43] T. Zander, J. A. Kraus, C. Grommes, et al., “Induction of apoptosis in human and rat glioma by agonists of the nuclear receptor PPARγ,” *Journal of Neurochemistry*, vol. 81, no. 5, pp. 1052–1060, 2002.

[44] C. Zang, M. Wächter, H. Liu, et al., “Ligands for PPARγ and RAR cause induction of growth inhibition and apoptosis in human glioblastomas,” *Journal of Neuro-Oncology*, vol. 65, no. 2, pp. 107–118, 2003.

[45] M. Kato, T. Nagaya, M. Fujieda, K. Saito, J. Yoshida, and H. Seo, “Expression of PPARγ and its ligand-dependent growth inhibition in human brain tumor cell lines,” *Japanese Journal of Cancer Research*, vol. 93, no. 6, pp. 660–666, 2002.

[46] R. Morosetti, T. Servidei, M. Mirabella, et al., “The PPARγ ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines,” *International Journal of Oncology*, vol. 25, no. 2, pp. 493–502, 2004.

[47] N. Strakova, J. Ehrmann, J. Bartos, J. Malikova, J. Dolezel, and Z. Kolář, “Peroxisome proliferator-activated receptors (PPAR)
agonists affect cell viability, apoptosis and expression of cell cycle related proteins in cell lines of glial brain tumors,” *Neoplasma*, vol. 52, no. 2, pp. 126–136, 2005.

[48] E. Benedetti, R. Galzio, B. Cinque, et al., “Biomolecular characterization of human glioblastoma cells in primary cultures: differentiating and antiangiogenic effects of natural and synthetic PPARγ agonists,” *Journal of Cellular Physiology*. In press.

[49] J. M. Pérez-Ortiz, P. Tranque, M. Burgos, C. F. Vaquero, and J. Llopis, “Glitazones induce astrogloma cell death by releasing reactive oxygen species from mitochondria: modulation of cytotoxicity by nitric oxide,” *Molecular Pharmacology*, vol. 72, no. 2, pp. 407–417, 2007.

[50] D. W. Kang, C. H. Choi, J. Y. Park, S. K. Kang, and Y. K. Kim, “Ciglitazone induces caspase-independent apoptosis through down-regulation of XIAP and survivin in human glioma cells,” *Neurochemical Research*, vol. 33, no. 3, pp. 551–561, 2008.

[51] C. Grommes, G. E. Landreth, U. Schlegel, and M. T. Heneka, “The nonthiazoledinedione tyrosine-based peroxisome proliferator-activated receptor γ ligand GW7845 induces apoptosis and limits migration and invasion of rat and human glioma cells,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 313, no. 2, pp. 806–813, 2005.

[52] C. Grommes, G. E. Landreth, M. Sastre, et al., “Inhibition of in vivo glioma growth and invasion by peroxisome proliferator-activated receptor γ agonist treatment,” *Molecular Pharmacology*, vol. 70, no. 5, pp. 1524–1533, 2006.

[53] D. Sugiyama, H. Kusuhara, H. Taniguchi, et al., “Functional characterization of rat brain specific organic anion transporter (Oatp14) at the blood-brain barrier: high affinity transporter for thyroxine,” *The Journal of Biological Chemistry*, vol. 278, no. 44, pp. 43489–43495, 2003.

[54] A. Spagnolo, E. N. Grant, R. Glick, T. Lichtor, and D. L. Feinstein, “Differential effects of PPARγ agonists on the metabolic properties of gliomas and astrocytes,” *Neuroscience Letters*, vol. 417, no. 1, pp. 72–77, 2007.

[55] A. Spagnolo, R. P. Glick, H. Lin, E. P. Cohen, D. L. Feinstein, and T. Lichtor, “Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor-γ thiazolidinedione agonists and interleukin-2-secreting syngeneic/allogeneic fibroblasts,” *Journal of Neurosurgery*, vol. 106, no. 2, pp. 299–305, 2007.

[56] R. Coras, A. Hulksen, S. Seufert, et al., “The peroxisome proliferator-activated receptor-γ agonist troglitazone inhibits transforming growth factor-β-mediated glioma cell migration and brain invasion,” *Molecular Cancer Therapeutics*, vol. 6, no. 6, pp. 1745–1754, 2007.

[57] F. Frasanna, A. Thibault, L. Liu, and D. Samid, “Lipid metabolism as a target for brain cancer therapy: synergistic activity of lovastatin and sodium phenylacetate against human glioma cells,” *Journal of Neurochemistry*, vol. 66, no. 2, pp. 710–716, 1996.

[58] C.-J. Yao, G.-M. Lai, C.-F. Chan, A.-L. Cheng, Y.-Y. Yang, and S.-E. Chuang, “Dramatic synergistic antiangiogenic effect of clinically achievable doses of lovastatin and troglitazone,” *International Journal of Cancer*, vol. 118, no. 3, pp. 773–779, 2006.

[59] D.-C. Liu, C.-B. Zang, H.-Y. Liu, K. Possinger, S.-G. Fan, and E. Elstner, “A novel PPAR alpha/gamma dual agonist inhibits cell growth and induces apoptosis in human glioblastoma T98G cells,” *Acta Pharmacologica Sinica*, vol. 25, no. 10, pp. 1312–1319, 2004.

[60] S. S. Palakurthi, H. Aktas, L. M. Grubissich, R. M. Mortensen, and J. A. Halperin, “Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor γ and mediated by inhibition of translation initiation,” *Cancer Research*, vol. 61, no. 16, pp. 6213–6218, 2001.

[61] C.-W. Shiau, C.-C. Yang, S. K. Kulp, et al., “Thiazolidinediones mediate apoptosis in prostate cancer cells in part through inhibition of Bcl-xl/Bcl-2 functions independently of PPARγ,” *Cancer Research*, vol. 65, no. 4, pp. 1561–1569, 2005.

[62] Y. Akasaki, G. Liu, H. H. Matundan, et al., “A peroxisome proliferator-activated receptor-γ agonist, troglitazone, facilitates caspase-8 and -9 activities by increasing the enzymatic activity of protein-tyrosine phosphatase-1B in human glioma cells,” *The Journal of Biological Chemistry*, vol. 281, no. 10, pp. 6165–6174, 2006.

[63] K. Schultz, B. Bock, A. Eckert, et al., “Troglitazone sensitizes tumor cells to TRAIL-induced apoptosis via down-regulation of FLIP and Survivin,” *Aptosis*, vol. 11, no. 9, pp. 1503–1512, 2006.

[64] D. Evans, W. A. Mann, J. de Heer, et al., “Variation in the gene for human peroxisome proliferator activated receptor γ (PPARγ) does not play a major role in the development of morbid obesity,” *International Journal of Obesity*, vol. 24, no. 5, pp. 647–651, 2000.

[65] W. M. Smith, X.-P. Zhou, K. Kurose, et al., “Opposite association of two PPARγ variants with cancer: overrepresentation of H449I in endometrial carcinoma cases and underrepresentation of P12A in renal cell carcinoma cases,” *Human Genetics*, vol. 109, no. 2, pp. 146–151, 2001.

[66] X.-P. Zhou, W. M. Smith, O. Gimm, et al., “Overrepresentation of PPARγ sequence variants in sporadic cases of glioblastoma multiforme: preliminary evidence for common low penetrance modifiers for brain tumour risk in the general population,” *Journal of Medical Genetics*, vol. 37, no. 6, pp. 410–414, 2000.

[67] T. Servidei, R. Morosetti, C. Ferlini, et al., “The cellular response to PPARγ ligands is related to the phenotype of neuroblastoma cell lines,” *Oncology Research*, vol. 14, no. 7-8, pp. 345–354, 2004.

[68] Y. Sato, H. Sasaki, Y. Kobayashi, et al., “Expression of PPAR-γ2 is correlated with the clinical course of neuroblastoma,” *Journal of Pediatric Surgery*, vol. 38, no. 2, pp. 205–210, 2003.

[69] S. W. Han, M. E. Greene, J. Pitts, R. K. Wada, and N. Sidell, “Novel expression and function of peroxisome proliferator-activated receptor gamma (PPARγ) in human neuroblastoma cells,” *Clinical Cancer Research*, vol. 7, no. 1, pp. 98–104, 2001.

[70] S. Di Loreto, B. D’Angelo, M. A. D’Amico, et al., “PPARγ agonists trigger neuronal differentiation in the human neuroblastoma cell line SH-SY5Y,” *Journal of Cellular Physiology*, vol. 213, no. 3, pp. 837–847, 2007.

[71] A. O. Isaac, I. Kawikova, A. L. M. Bothwell, C. K. Daniels, and J. C. K. Lai, “Manganese treatment modulates the expression of peroxisome proliferator-activated receptors in astrocytoma and neuroblastoma cells,” *Neurochemical Research*, vol. 31, no. 11, pp. 1305–1316, 2006.

[72] A. Bonfigli, O. Zarivi, S. Colafarina, et al., “Human glioblastoma ADF cells express tyrosinase, L-tyrosine hydroxylase and melanosomes and are sensitive to L-tyrosine and phenylethiourea,” *Journal of Cellular Physiology*, vol. 207, no. 3, pp. 675–682, 2006.

[73] G. C. Burdge, H. Rodway, J. A. Kohler, and K. A. Lillycrop, “Effect of fatty acid supplementation on growth and differ-
entiation of human IMR-32 neuroblastoma cells in vitro,” *Journal of Cellular Biochemistry*, vol. 80, no. 2, pp. 266–273, 2000.

[74] H. A. Rodway, A. N. Hunt, J. A. Kohler, A. D. Postle, and K. A. Lillycrop, “Lysophosphatidic acid attenuates the cytotoxic and degree of peroxisome proliferator-activated receptor γ activation induced by 15-deoxyΔ12,14'-prostaglandin J2 in neuroblastoma cells,” *Biochemical Journal*, vol. 382, no. 1, pp. 83–91, 2004.

[75] V. C. Emmans, H. A. Rodway, A. N. Hunt, and K. A. Lillycrop, “Regulation of cellular processes by PPARγ ligands in neuroblastoma cells is modulated by the level of retinoblastoma protein expression,” *Biochemical Society Transactions*, vol. 32, no. 5, pp. 840–842, 2004.

[76] E. J. Kim, K. S. Park, S. Y. Chung, et al., “Peroxisome proliferator-activated receptor-γ activator 15-deoxy-Δ12,14'-prostaglandin J2 inhibits neuroblastoma cell growth through induction of apoptosis: association with extracellular signal-regulated kinase signal pathway,” *Journal of Pharmacology and Experimental Therapeutics*, vol. 307, no. 2, pp. 505–517, 2003.

[77] A. Rossi, P. Kapahi, G. Natoli, et al., “Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of IκB kinase,” *Nature*, vol. 403, no. 6765, pp. 103–118, 2000.

[78] U. Valentiner, M. Carlsson, R. Erttmann, H. Hildebrandt, and U. Schumacher, “Ligands for the peroxisome proliferator-activated receptor-γ have inhibitory effects on growth of human neuroblastoma cells in vitro,” *Toxicology*, vol. 213, no. 1-2, pp. 157–168, 2005.

[79] I. Cellai, S. Benvenuti, P. Luciani, et al., “Antineoplastic effects of rosiglitazone and PPARγ transactivation in neuroblastoma cells,” *British Journal of Cancer*, vol. 95, no. 7, pp. 879–888, 2006.

[80] T. W. Jung, J. Y. Lee, W. S. Shim, et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity,” *Biochemical and Biophysical Research Communications*, vol. 340, no. 1, pp. 221–227, 2006.

[81] T. W. Jung, J. Y. Lee, W. S. Shim, et al., “Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP7-induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production,” *Journal of the Neurological Sciences*, vol. 253, no. 1-2, pp. 53–60, 2007.

[82] P. Hau, L. Kunz-Schughart, U. Bogdahn, et al., “Low-dose chemotherapy in combination with COX-2 inhibitors and PPAR-gamma agonists in recurrent high-grade gliomas—a phase II study,” *Oncology*, vol. 73, no. 1-2, pp. 21–25, 2008.